It is predicted that this discovery will put greater emphasis "on so-called drug repositioning as a way of lowering the costs of drug development and getting therapies to patients more quickly," according to a Wall Street Journal article (here).
There's only one catch: "an advantage of finding repurposed drugs is that, since they are already approved, doctors can prescribe them off-label for patients," says WSJ. "This opens the door to very low-cost, individualized personal therapies," said Yves A. Lussier, a professor of medicine and engineering at the University of Illinois at Chicago who wasn't associated with the study.
Yeah, but if the drug is too old -- ie, off-patent -- no branded drug company will be interested in getting the drug approved for a new indication UNLESS a new USE patent can be obtained. THAT's exactly what Pfizer did to extend the patent life of VIAGRA (see "Double-Dip Viagra Patent Means No Recession for Pfizer").
[This post originally appeared in Pharma Marketing Blog.
Make sure you are reading the source to get the latest comments.]